Cell Reports · 2013 · 149 citations · 65 references
MedicineMolecular BiologyOncologyCancer GeneticsEpigeneticsMolecular OncologyEpigenetic Regulation In CancerGene Fusions In CancerOncogene ActivationOncogenic Fusion GenesProto-oncogene ActivationTranscription Factor OncogenesEpigenetic Gene ActivationGene Activation MechanismsGene Fusion OncoproteinsLeukemia PathologyLeukemia-associated Fusion GenesOncogenic Fusion MechanismsOncogenic Fusion ProteinsRunx Family Oncogenes
The Mixed Lineage Leukemia (MLL) protein is an important epigenetic regulator required for the maintenance of gene activation during development. MLL chromosomal translocations produce novel fusion proteins that cause aggressive leukemias in humans. Individual MLL fusion proteins have distinct leukemic phenotypes even when expressed in the same cell type, but how this distinction is delineated on a molecular level is poorly understood. Here, we highlight a unique molecular mechanism whereby the RUNX1 gene is directly activated by MLL-AF4 and the RUNX1 protein interacts with the product of the reciprocal AF4-MLL translocation. These results support a mechanism of transformation whereby two oncogenic fusion proteins cooperate by activating a target gene and then modulating the function of its downstream product.
65
Fast and accurate short read alignment with Burrows–Wheeler transform
Heng Li, Richard Durbin · Bioinformatics · 2009 · 62.8K citations · Full text
RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia
Johannes Zuber, Junwei Shi, Eric Wang et al. · Nature · 2011 · 1.9K citations
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson, Rab K. Prinjha, Antje Dittmann et al. · Nature · 2011 · 1.5K citations · Full text